GLP toxicology studies

Australis is a global biopharmaceutical company developing cancer therapies, centered on its lead compound AUS_001, a naturally derived compound discovered in honeybee propolis from Kangaroo Island. Its in-house research is based at a laboratory in Simi Valley, California, staffed by PhD scientists, with third-party research performed worldwide. AUS_001 has shown pre-clinical efficacy against 24 types of cancer and has received FDA Orphan Drug Designation for malignant gliomas and Rare Pediatric Disease Designation for pediatric-type diffuse high-grade g

Read more

clinical trial developmentdrug formulationin vitro and in vivo studiespre-clinical research

Duo Oncology is a clinical-stage company developing tumor-activated drug conjugates designed to transform toxic multi-agent chemotherapy regimens into single medicines that concentrate therapeutic activity in tumors while limiting healthy-tissue exposure. Its lead clinical-stage product, DUO-207, combines gemcitabine and paclitaxel into a single-infusion, tumor-metabolized conjugate intended as a next-generation chemotherapy backbone for the KRAS inhibitor era.

Read more

clinical trial development (Phase 1b/2)preclinical pharmacologytumor-activated drug conjugate development